Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2016 -- Tobira Therapeutics, Inc. (NASDAQ:TBRA), a biopharmaceutical company developing novel treatments for nonalcoholic steatohepatitis (NASH), and other serious immuno-inflammatory and fibrotic diseases, will report financial results for the quarter ended December 31, 2015 after market close on Thursday March 3, 2016. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.
Date: March 3, 2016
Time: 1:30 PM PT
Listen via Internet: http://ir.tobiratherapeutics.com/
Schedule this webcast into MS-Outlook calendar (click open when prompted):
http://apps.shareholder.com/PNWOutlook/t.aspx?m=71315&k=7CAD412C
Toll-free: 1 (855) 638-8858
International: +1 (707) 294-1299
Password: 47016109
A webcast replay will be available on the Tobira Web site for 30 days. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1 (855) 859-2056 for domestic callers, or +1 (404) 537-3406 for international callers, and entering reservation code 47016109.
About Tobira Therapeutics, Inc.
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH). Learn more about Tobira at www.tobiratherapeutics.com.
CONTACT: Tobira Investor & Media Contact
Ian Clements, PhD
+1 (650) 351-5013
[email protected]
Canale Communications Media Contact
Pam Lord
+1 (619) 849-6003
[email protected]
